Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration

Ophthalmology

Volumn 115, Issue 12, 2008, Pages 2192-2198

  Fletcher, E C ^a   Lade, R J ^b   Adewoyin, T ^a   Chong, N V ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Kidde Plc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

ARTICLE; BLINDNESS; CASE STUDY; CLINICAL EFFECTIVENESS; COMPUTER MODEL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG UTILIZATION; EYE CARE; HEALTH CARE COST; HUMAN; PATIENT CARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; SHAM PROCEDURE; VISION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION TREES; HUMANS; MACULAR DEGENERATION; MODELS, ECONOMIC; PHOTOCHEMOTHERAPY; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 56549093417     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.07.018     Document Type: Article

References (18)

1. Soubrane G., Creuss A., Lotery A., et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 125 (2007) 1249-1254
2. Meads C., Salas C., Roberts T., et al. Clinical effectiveness and cost utility of photodynamic therapy for wet age-related macular degeneration (2002), West Midlands Health Technology Assessment Group, University of Birmingham, Birmingham, UK. http://www.nice.org.uk/nicemedia/pdf/maculardegenerationassessmentreport.pdf 16. Available at: http://www.nice.org.uk/nicemedia/pdf/maculardegenerationassessmentreport.pdf. Accessed August 5, 2008
3. Sharma S., Brown G.C., Brown M.M., et al. Converting visual acuity to utilities. Can J Ophthalmol 35 (2000) 267-272
4. Brown M.M., Brown G.C., Brown H., and Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 115 (2008) 1039-1045
5. Brown G.C., Brown M.M., Sharma S., et al. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 99 (2001) 199-203
6. Brown M.M., Brown G.C., Sharma S., et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 85 (2001) 327-331
7. Kaiser P.K., and Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244 (2006) 1132-1142
8. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 1508-1521
9. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
10. Regillo C.D., Brown D.M., Abraham P., et al., PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 (2008) 239-248
11. Dempster M., and Donnelly M. Measuring the health related quality of life of people with ischaemic heart disease. Heart 83 (2000) 641-644
12. Pickard A.S., Johnson J.A., and Feeny D.H. Responsiveness of generic health-related quality of life measures in stoke. Qual Life Res 14 (2005) 207-219
13. Sharma S., Brown G.C., Brown M.M., et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 108 (2001) 2051-2059
14. Meads C., and Hyde C. What is the cost of blindness?. Br J Ophthalmol 87 (2003) 1201-1204
15. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization?. Tentative guidelines for using clinical and economic evaluations. CMAJ 146 (1992) 473-481
16. Bansback N., Davis S., and Brazier J. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye 21 (2007) 1455-1463
17. Nguyen N.X., Besch D., Bartz-Schmidt K., et al. Reading performance with low-vision aids and vision-related quality of life after macular translocation surgery in patients with age-related macular degeneration. Acta Ophthalmol Scand 85 (2007) 877-882
18. Bansback N., Czoski-Murray C., Carlton J., et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res 16 (2007) 533-543